论文部分内容阅读
非酒精性脂肪性肝病发病率不断升高且有低龄化趋势。非酒精性脂肪性肝病除可导致终末期肝病和肝癌外,还与冠心病关系密切。非酒精性脂肪性肝病患者冠心病相关残疾和死亡显著增加,并且非酒精性脂肪性肝病和不明原因的肝酶持续异常可独立预测动脉硬化和冠心病的发生。非酒精性脂肪性肝病伴随的氧化应激,脂联素减少而瘦素、抵抗素增多,以及饱餐后血脂的代谢异常,可能对血管内皮细胞产生损害,从而参与动脉硬化的发生和发展。非酒精性脂肪性肝病的基础治疗为通过改变生活方式以控制体重和腰围,伴有冠心病的病例可试用胰岛素增敏剂、抗氧化药、降脂药、保肝药,而胰高血糖素样肽1受体激动剂以及大麻受体1拮抗剂等新药仍在研究中。
The incidence of non-alcoholic fatty liver disease continues to rise and the trend of younger age. In addition to non-alcoholic fatty liver disease can lead to end-stage liver disease and liver cancer, but also with coronary heart disease are closely related. Non-alcoholic fatty liver disease patients with coronary heart disease-related disabilities and death increased significantly, and persistent non-alcoholic fatty liver disease and unexplained liver enzymes can independently predict atherosclerosis and coronary heart disease. Non-alcoholic fatty liver disease accompanied by oxidative stress, decreased adiponectin and leptin, resistin increased, and the metabolic abnormalities of blood lipids after meal, may damage vascular endothelial cells, and thus involved in the occurrence and development of atherosclerosis. The basic treatment of non-alcoholic fatty liver disease by changing the lifestyle to control body weight and waist circumference, coronary heart disease cases can try insulin sensitizers, anti-oxidants, lipid-lowering drugs, hepatoprotective drugs, and glucagon New drugs like peptide 1 receptor agonists and cannabinoid receptor 1 antagonists are still under study.